[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.120.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Practice Gaps
April 2013

Propranolol to Treat Hemangiomas of Infancy: Safety and Side Effect RecognitionComment on “Retrospective Review of Adverse Effects from Propranolol in Infants”

Author Affiliations

Author Affiliations: Departments of Dermatology and Child Health, University of Missouri, Columbia.

JAMA Dermatol. 2013;149(4):481-504. doi:10.1001/jamadermatol.2013.3

In 2008, systemic administration of β-adrenergic blockers was found to dramatically improve hemangiomas of infancy (HOI).1 This watershed event of a new use for an established drug in the pediatric dermatologic treatment of HOI changed treatment protocols around the world.2 Concern has been raise about possible overtreatment of HOI now, compared with prior to 2008, but the change in treatment of HOI is more likely owing to the lack of low-risk interventions prior to 2008 than to current overtreatment.

First Page Preview View Large
First page PDF preview
First page PDF preview
×